In response to future pandemic preparedness planning (say that 3x real fast), particulrarly for influenza outbreaks, the Japanesese goverment is encouraging Takeda and Baxter to collaborate on a new cell-culture based vacine manufacturing center of excellence in Japan.
Takeda will be responsible for buidlign a Vero-based influenza production facility, and Baxter will support them with technology know-how to produce the flu vaccine. Takeda expects to be able to to produce a H5N1 vaccine at full scale by end of March 2014.
Takeda and Baxter will apply for 3.6 B yen ($42.9 M) from the Japanes government to invest in pandemic vaccines. Baxter will provide an exclusive license to its Vero-based technology toTakeda for the Japanese market. Baxter claims the same technology shortened the response time in preparing H1N1 vaccines as it eliminated the time-consuming adaptation to allow growth of the virus in eggs - and Vero-based manufacturing is more consistent and predictable too.
Posted by Bruce Lehr December 8th 2010.